A new study by the University of Oxford, published in the journal npj Vaccines, shows that a vaccine against respiratory ...

Using informed consent to do what Congress couldn’t, the U.S. FDA is flexing its regulatory authority to halt clinical trials that involve sending cells from American patients to China or other ...

Researchers from the National Cancer Institute and their collaborators have presented data regarding a MLK3-degrading PROTAC, CEP1347-VHL-02, for treating triple-negative breast cancer.

Neurons talk to one another using electricity. If you could hear these impulses, they might sound like constant, rapid-fire chatter all over the nervous system. Heart muscle cells do something ...

The promise of stem cell therapy is powerful. Scientists can draw versatile cells from the human body and deliver them to repair injuries and fight disease from the inside out. But not all stem ...

Cuts in NIH grants and the threat of more are discouraging investment and may drive trials out of the United States.

Since 2009, the maximum efficiency of perovskite solar cells has risen from 3.9% to 30.1% —it took 37 years for crystalline silicon solar cells to achieve comparable efficiencies.

First vascularized model of stem cell islet cells Date: May 23, 2025 Source: Max Delbrück Center for Molecular Medicine in the Helmholtz Association Summary: Researchers have developed a ...

Introduction Respiratory syncytial virus (RSV) is a common respiratory virus consisting of two subgroups: RSV-A and RSV-B. It causes a range of clinical symptoms from asymptomatic infection/mild upper ...

Scientists from The University of Manchester have changed our understanding of how cells in living organisms divide, which could revise what students are taught at school. In a study published ...

Background The mechanisms regulating antibody expression within the human lung during airway infection are largely unknown. In this study, our objectives were to determine if infection with ...

Results from a Phase III clinical trial, including two-year follow-up data, show that ArkBio’s ziresovir (AK0529), a novel antiviral for respiratory syncytial virus (RSV), is the first therapy in its ...